Team approach to manage difficult-to-treat TB cases: Experiences in Europe and beyond

Archive ouverte

D’ambrosio, L. | Bothamley, G. | Caminero Luna, J.A., A | Duarte, R. | Guglielmetti, L. | Muñoz Torrico, M. | Payen, M., C | Saavedra Herrera, N. | Salazar Lezama, M., A | Skrahina, A. | Tadolini, M. | Tiberi, S. | Veziris, N. | Migliori, G.

Edité par CCSD ; Taylor & Francis -

International audience. As recommended by the World Health Organization (WHO), optimal management of MDR-TB cases can be ensured by a multi-speciality consultation body known as 'TB Consilium'. This body usually includes different medical specialities, competences and perspectives (e.g., clinical expertise both for adults and children; surgical, radiological and public health expertise; psychological background and nursing experience, among others), thus lowering the risk of making mistakes - or managing the patients inappropriately, in order to improve their clinical outcomes. At present, several high MDR-TB burden countries in the different WHO regions (and beyond) have introduced TB Consilium-like bodies at the national or subnational level to reach consensus on the best treatment approach for their patients affected by TB. In addition, in countries/settings where a formal system of consultation does not exist, specialized staff from MDR-TB reference centres or international organizations usually spend a considerable amount of their working time responding to phone or e-mail clinical queries on how to manage M/XDR-TB cases. The aim of this manuscript is to describe the different experiences with the TB Consilia both at the international level (European Respiratory Society - ERS/WHO TB Consilium) and in some of the countries where this experience operates successfully in Europe and beyond. The Consilium experiences are described around the following topics: (1) history, aims and focus; (2) management and funding; (3) technical functioning and structure; (4) results achieved. In addition a comparative analysis of the TB Consilia in the different countries has been performed.

Suggestions

Du même auteur

TB and COVID-19 co-infection: rationale and aims of a global study

Archive ouverte | Gallegos, P. | CCSD

International audience

Management of patients with multidrug-resistant tuberculosis

Archive ouverte | Lange, C. | CCSD

International audience

Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy

Archive ouverte | Kuksa, L. | CCSD

International audience. Pretomanid is a key anti-TB drug included in the WHO list of essential medications. The current EMA-approved label for pretomanid restricts its use to the regimen comprising bedaquiline, pret...

Chargement des enrichissements...